☆ 4.3 Article

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

Oncotarget (2018)

Journal

Oncotarget

Volume 9, Issue 20, Pages -

Publisher

Impact Journals, LLC

DOI: 10.18632/oncotarget.24573

Keywords

-

Categories

-

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.